Log In
BCIQ
Print this Print this
 

miR-103/107 (AZD4076, RG-125)

  Manage Alerts
Collapse Summary General Information
Company Regulus Therapeutics Inc.
DescriptionGalNAc-conjugated anti-miR targeting microRNA-103/107
Molecular Target MicroRNA-103 (miR-103) ; MicroRNA-107 (miR-107)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPhase I
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH) in Type II diabetics or prediabetics
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today